Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista brasileira de hematologia e hemoterapia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406 |
Resumo: | ABSTRACT Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil. |
id |
ABHHTC-1_02ee157d83f5ac7a8ebc24e925bed8ab |
---|---|
oai_identifier_str |
oai:scielo:S1516-84842015000600406 |
network_acronym_str |
ABHHTC-1 |
network_name_str |
Revista brasileira de hematologia e hemoterapia (Online) |
repository_id_str |
|
spelling |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemiaMinimal residual diseaseMRD acute lymphoblastic leukemiaFlow cytometryImmunophenotypingABSTRACT Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406Revista Brasileira de Hematologia e Hemoterapia v.37 n.6 2015reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1016/j.bjhh.2015.07.012info:eu-repo/semantics/openAccessIkoma,Maura Rosane ValérioBeltrame,Miriam PerlingeiroFerreira,Silvia Inês Alejandra Cordoba PiresSouto,Elizabeth XistoMalvezzi,MariesterYamamoto,Mihokoeng2016-01-07T00:00:00Zoai:scielo:S1516-84842015000600406Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2016-01-07T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false |
dc.title.none.fl_str_mv |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
title |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
spellingShingle |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia Ikoma,Maura Rosane Valério Minimal residual disease MRD acute lymphoblastic leukemia Flow cytometry Immunophenotyping |
title_short |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
title_full |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
title_fullStr |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
title_full_unstemmed |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
title_sort |
Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia |
author |
Ikoma,Maura Rosane Valério |
author_facet |
Ikoma,Maura Rosane Valério Beltrame,Miriam Perlingeiro Ferreira,Silvia Inês Alejandra Cordoba Pires Souto,Elizabeth Xisto Malvezzi,Mariester Yamamoto,Mihoko |
author_role |
author |
author2 |
Beltrame,Miriam Perlingeiro Ferreira,Silvia Inês Alejandra Cordoba Pires Souto,Elizabeth Xisto Malvezzi,Mariester Yamamoto,Mihoko |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Ikoma,Maura Rosane Valério Beltrame,Miriam Perlingeiro Ferreira,Silvia Inês Alejandra Cordoba Pires Souto,Elizabeth Xisto Malvezzi,Mariester Yamamoto,Mihoko |
dc.subject.por.fl_str_mv |
Minimal residual disease MRD acute lymphoblastic leukemia Flow cytometry Immunophenotyping |
topic |
Minimal residual disease MRD acute lymphoblastic leukemia Flow cytometry Immunophenotyping |
description |
ABSTRACT Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjhh.2015.07.012 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia v.37 n.6 2015 reponame:Revista brasileira de hematologia e hemoterapia (Online) instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
instname_str |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
instacron_str |
ABHHTC |
institution |
ABHHTC |
reponame_str |
Revista brasileira de hematologia e hemoterapia (Online) |
collection |
Revista brasileira de hematologia e hemoterapia (Online) |
repository.name.fl_str_mv |
Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
repository.mail.fl_str_mv |
sbhh@terra.com.br||secretaria@rbhh.org |
_version_ |
1754213112779636736 |